<DOC>
	<DOCNO>NCT02813785</DOCNO>
	<brief_summary>This Phase III , multicenter , open-label , randomize , control study design evaluate efficacy safety anti-programmed death-ligand 1 ( PD-L1 ) antibody atezolizumab compare docetaxel participant locally advance metastatic NSCLC progress follow platinum-containing regimen . Treatment may continue disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Atezolizumab Compared With Docetaxel Non-Small Cell Lung Cancer ( NSCLC ) After Failure With Platinum-Containing Chemotherapy IMpower210</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically document , locally advanced metastatic NSCLC Representative formalinfixed paraffinembedded ( FFPE ) tumor specimens available least 12 unstained , freshly cut serial section associate pathology report evaluable PDL1 expression epidermal growth factor receptor ( EGFR ) mutation status prior enrollment , except know sensitize EGFR mutation case 10 unstained slide require need central test EGFR mutation status Disease progression follow treatment prior platinumcontaining regimen locally advance , unresectable , inoperable , metastatic NSCLC , disease recurrence within 6 month treatment platinumbased adjuvant and/or neoadjuvant regimen combine modality curative intent Measurable disease per RECIST Version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great equal ( &gt; /= ) 12 week Adequate hematologic end organ function Agreement remain abstinent use contraceptive method among woman childbearing potential male partner woman childbearing potential Recovery acute toxicity previous therapy Active untreated central nervous system ( CNS ) metastases Spinal cord compression definitively treat clinically stable Leptomeningeal disease Uncontrolled pleural pericardial effusion ascites require recurrent drainage Uncontrolled tumorrelated pain Uncontrolled hypercalcemia Malignancies NSCLC within 5 year prior randomization , except curatively treat negligible risk metastasis death Pregnant lactate woman Significant cardiovascular , pulmonary , autoimmune disease Severe infection major surgery within 4 week , antibiotic treatment within 2 week prior randomization Prior treatment hypersensitivity study drug ( ) relate compound Inability discontinue strong cytochrome P450 ( CYP ) 3A4 inhibitor Prior allogeneic bone marrow solid organ transplant Known PDL1 expression status clinical study Positive human immunodeficiency virus ( HIV ) hepatitis B C Receipt live attenuate vaccine within 4 week prior randomization Treatment systemic immunomodulators within 4 week five halflives ( whichever short ) prior randomization Treatment systemic corticosteroid within 2 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>